SG Americas Securities LLC Trims Stake in CRISPR Therapeutics AG $CRSP

SG Americas Securities LLC decreased its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 73.0% in the first quarter, Holdings Channel.com reports. The firm owned 3,737 shares of the company’s stock after selling 10,097 shares during the quarter. SG Americas Securities LLC’s holdings in CRISPR Therapeutics were worth $178,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Fund Advisors of America Inc FL purchased a new stake in CRISPR Therapeutics in the fourth quarter worth about $398,000. Virtu Financial LLC purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter worth approximately $862,000. Mcguire Capital Advisors Inc. bought a new position in CRISPR Therapeutics during the 4th quarter valued at approximately $25,000. Axxcess Wealth Management LLC increased its position in CRISPR Therapeutics by 6.2% during the 4th quarter. Axxcess Wealth Management LLC now owns 13,022 shares of the company’s stock valued at $683,000 after buying an additional 764 shares in the last quarter. Finally, Corient Private Wealth LLC raised its stake in CRISPR Therapeutics by 5.7% during the fourth quarter. Corient Private Wealth LLC now owns 8,566 shares of the company’s stock valued at $449,000 after buying an additional 460 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Naimish Patel sold 3,786 shares of CRISPR Therapeutics stock in a transaction on Friday, May 29th. The stock was sold at an average price of $55.62, for a total value of $210,577.32. Following the completion of the sale, the insider owned 19,357 shares of the company’s stock, valued at $1,076,636.34. The trade was a 16.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.30% of the stock is currently owned by company insiders.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ:CRSP traded down $2.99 during midday trading on Friday, reaching $53.35. 2,069,985 shares of the company’s stock traded hands, compared to its average volume of 1,550,007. The company has a debt-to-equity ratio of 0.32, a quick ratio of 17.96 and a current ratio of 17.97. CRISPR Therapeutics AG has a one year low of $44.12 and a one year high of $78.48. The company has a market cap of $5.15 billion, a price-to-earnings ratio of -8.58 and a beta of 1.71. The stock has a 50 day moving average of $53.46 and a 200 day moving average of $53.17.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, March 31st. The company reported ($1.28) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. The company had revenue of $1.46 million for the quarter. As a group, equities research analysts anticipate that CRISPR Therapeutics AG will post -4.89 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CRSP has been the topic of several analyst reports. Citizens Jmp reissued a “market outperform” rating and issued a $80.00 target price on shares of CRISPR Therapeutics in a report on Monday, July 6th. Morgan Stanley set a $60.00 price target on CRISPR Therapeutics and gave the stock an “equal weight” rating in a research report on Thursday, June 11th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday. Citigroup reissued a “market outperform” rating on shares of CRISPR Therapeutics in a research report on Wednesday, May 27th. Finally, Piper Sandler restated an “overweight” rating and set a $110.00 price objective (up from $105.00) on shares of CRISPR Therapeutics in a research note on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $67.78.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.